"Alemtuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.
| Descriptor ID |
D000074323
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.313 D12.776.124.790.651.114.224.060.375 D12.776.377.715.548.114.224.200.375
|
| Concept/Terms |
Campath 1H- Campath 1H
- Monoclonal Antibody Campath-1H
- Antibody Campath-1H, Monoclonal
- Campath-1H, Monoclonal Antibody
- Monoclonal Antibody Campath 1H
- Campath-1H
- Campath1H
Campath 1G- Campath 1G
- Campath-1-G
- Campath 1 G
- Campath1G
- Campath-1G
|
Below are MeSH descriptors whose meaning is more general than "Alemtuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Alemtuzumab [D12.776.124.486.485.114.224.060.313]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Alemtuzumab [D12.776.124.790.651.114.224.060.375]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Below are MeSH descriptors whose meaning is more specific than "Alemtuzumab".
This graph shows the total number of publications written about "Alemtuzumab" by people in this website by year, and whether "Alemtuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 5 | 5 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alemtuzumab" by people in Profiles.
-
Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience. Bone Marrow Transplant. 2021 11; 56(11):2797-2803.
-
Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant. Pediatr Blood Cancer. 2018 12; 65(12):e27348.
-
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018 09 27; 132(13):1438-1451.
-
High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
-
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant. 2013 Oct; 48(10):1324-8.
-
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):287-91.
-
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.
-
Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol. 2009 Sep 30; 26(3):175-83.
-
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):610-7.
-
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73.